Promising New Molecular Targeted Therapies in Head and Neck Cancer
Promising New Molecular Targeted Therapies in Head and Neck Cancer
复制标题
DOI：
10.1007/s40265-013-0025-3
复制
发表时间：
2013-01-01
期刊：
影响因子：
11.5
通讯作者：
Agulnik, Mark
中科院分区：
文献类型：
--
作者：
Dorsey, Kelly;Agulnik, Mark
尽管治疗头颈鳞状细胞癌（SCCHN）的多学科疗法取得了进展，但生存率、功能结果和治疗毒性仍然很低。对人乳头瘤病毒 (HPV) 状态的预后价值的认识，以及具有降低毒性和增加选择性的潜力的生物靶向疗法的出现，代表了我们对 SCCHN 理解的重大进展。目前批准或正在研究的 SCCHN 靶向药物包括表皮生长因子受体 (EGFR) 单克隆抗体（西妥昔单抗、帕尼单抗、扎鲁木单抗、尼妥珠单抗）、EGFR 酪氨酸激酶抑制剂（吉非替尼、厄洛替尼、拉帕替尼、阿法他尼、达克替尼）、血管内皮生长因子受体 (VEGFR) 抑制剂（贝伐单抗、索拉非尼、舒尼替尼、 vandetanib）以及其他途径和靶点的各种抑制剂，包括磷脂酰肌醇 3' 激酶 (PI3K)/AKT/雷帕霉素哺乳动物靶点 (mTOR)、MET 和胰岛素样生长因子受体 (IGF-1R)。正在进行的临床试验正在评估这些新兴药物及其组合在 SCCHN 治疗中的作用。
Despite advances in multimodality therapies for the treatment of squamous cell carcinoma of the head and neck (SCCHN), survival rates, functional outcomes and toxicities of therapy remain poor. The recognition of the prognostic value of human papillomavirus (HPV) status, and the advent of biologically targeted therapies with potential for decreased toxicities and increased selectivity, represent significant developments in our understanding of SCCHN. Targeted agents currently approved or under investigation for SCCHN include epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab, zalutumumab, nimotuzumab), EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib, afatanib, dacomitinib), vascular endothelial growth factor receptor (VEGFR) inhibitors (bevacizumab, sorafenib, sunitinib, vandetanib) and various inhibitors of other pathways and targets, including phosphatidylinositol 3' kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), MET and insulin-like growth factor receptor (IGF-1R). On-going clinical trials are evaluating these emerging agents and their combinations in the treatment of SCCHN.